Massive french study to reveal best way to harvest donor livers
NCT ID NCT07582978
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This large French study will follow 1,810 adults receiving their first liver transplant to see if the way the donor liver is removed affects outcomes. The main focus is on avoiding artery and bile duct complications for three years after transplant. The goal is to identify the best procurement technique to improve patient recovery.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help surgeons choose the best procurement method to reduce complications after liver transplantation.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly test a new therapy, and results may not lead to immediate changes in practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,810 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
adult patients (≥18 years) who undergo a first liver transplantation in France.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patients aged 18 years or older at the time of inclusion 2. Listed on the national waiting list of the Agence de la Biomédecine (ABM) 3. Undergoing a first liver transplantation in France 4. Receiving a whole liver graft 5. No prior or subsequent transplantation of another organ Exclusion Criteria: 1. Pancreas procurement 2. Multiorgan transplantation 3. Split liver transplantation (shared grafts) 4. Retransplantation 5. Domino transplantation (no actual organ procurement in the conventional sense) 6. Patient refusal to allow the use of their data
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for End-stage liver disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sugar patterns in blood may foretell liver transplant rejection
- Can better training get doctors to talk about what matters most to dying veterans?
- Could a mask replace the breathing tube in liver transplants?
- Can immune cells predict herpesvirus danger in transplant patients?
- Muscle quality on MRI may foretell liver transplant success
- A new Anti-Rejection strategy may spare kidney function after liver transplant